- 8 Lasseter GM, McNulty CAM, Hobbs FDR, Mant D, Little P. *In vitro* evaluation of five rapid antigen detection tests for group A beta-haemolytic streptococcal sore throat infections. *Fam Pract* 2009; **26**: 437–44.
- 9 Drake C, Barenfanger J, Lawhorn J, Verhulst S. Comparison of Easy-Flow Copan liquid Stuart's and Starplex swab transport systems for recovery of fastidious aerobic bacteria. *J Clin Microbiol* 2005; **43**: 1301–3.
- 10 Österblad M, Järvinen H, Lönnqvist K *et al.* Evaluation of a new cellulose sponge-tipped swab for microbiological sampling: a laboratory and clinical investigation. *J Clin Microbiol* 2003; **41**: 1894–900.
- 11 Roelofsen E, van Leeuwen M, Meijer-Severs GJ, Wilkinson MHF, Degener JE. Evaluation of the effects of storage in two different swab fabrics and under three different transport conditions on recovery of aerobic and anaerobic bacteria. *J Clin Microbiol* 1999; **37**: 3041–3.
- 12 Van Horn KG, Audette CD, Tucker KA, Sebeck D. Comparison of three swab transport systems for direct release and recovery of aerobic and anaerobic bacteria. *Diagn Microbiol Infect Dis* 2008; **62**: 471–3.
- 13 Scansen KA, Bonsu BK, Stoner E *et al*. Comparison of polyurethane foam to nylon flocked swabs for collection of secretions from the anterior nares in performance of a rapid influenza virus antigen test in a pediatric emergency department. *J Clin Microbiol* 2010; **8**: 852–6.
- 14 Gerber M. Diagnosis of group A beta-hemolytic streptococcal pharyngitis: use of antigen detection tests. *Diagn Microbiol Infect Dis* 1986; **4** (3 Suppl): 5S–15S.

Comparison of the identification of *Acinetobacter* spp. with API20NE and 16S rRNA gene sequencing techniques

A. J. McCARRON*†, J. XU*‡, C. ARMSTRONG[§], G. GLYNN#, B. C. MILLAR* , R. B. McCLURG* , L. HAN‡ , C. E. GOLDSMITH* , P. J. ROONEY* and J. E. MOORE**

** Northern Ireland Public Health Laboratory, Department of Bacteriology, Belfast City Hospital, Belfast; † School of Biomedical Sciences, Centre for Molecular Biosciences, University of Ulster, Coleraine, Northern Ireland; ‡ Department of Immunology and Pathogenic Biology, Molecular Bacteriology Laboratory, Key Laboratory of Environment and Genes related to Diseases of Chinese Ministry of Education, School of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China; § Department of Microbiology, Craigavon Area Hospital, Craigavon, Co. Armagh; and #Department of Microbiology, Altnagelvin Hospital, Glenshane Road, Londonderry, Co. Londonderry, Northern Ireland.*

Acinetobacter species are aerobic, encapsulated, oxidasenegative, non-motile, non-fermentative Gram-negative coccobacilli. Until recently, the genus *Acinetobacter* contained the single species *A. calcoaceticus*, which was subdivided into two subspecies or biovars (*A. calcoaceticus* subspecies *anitratus* and *A. calcoaceticus* subspecies *Iwoffii*). In 1986, the taxonomy of the genus *Acinetobacter* was altered extensively

Correspondence to: Professor John E. Moore Northern Ireland Public Health Laboratory, Department of Bacteriology Belfast City Hospital, Belfast BT9 7AD, Northern Ireland Email: jemoore@niphl.dnet.co.uk

by Bouvet and Grimont,¹ who outlined 12 different species by DNA-DNA hybridisation, including the named species *A. baumannii, A. calcoaceticus, A. haemolyticus, A. johnsonii, A. junii,* and *A. Iwoffii*, and six unnamed genomic species. More recently, 16S rRNA gene sequence analysis has also revealed that *Acinetobacter* spp. represent a well-defined genus;² however, species delineation has been more problematic and although a total of 24 genomic species have so far been recognised, only nine have been provided with valid species names.³ At present, there are 23 formally described species with standing in the literature, which include *A. baumannii, A. baylyi, A. beijerinckii, A. bereziniae, A. bouvetii, A. calcoaceticus, A. gerneri, A. guillouiae, A. grimontii, A. gyllenbergii, A. haemolyticus, A. johnsonii, A. junii, A. Iwoffii, A. parvus, A. radioresistens, A. schindleri, A. soli, A. tandoii, A. tjernbergiae, A. towneri, A. ursingii* and *A. venetianus* (www.bacterio.cict.fr/a/acinetobacter.html).

Acinetobacter species are opportunistic pathogens of low virulence. They are widely prevalent in nature, being found on both animate and inanimate objects.4 Although generally regarded as commensals of the skin and the respiratory and genitourinary tracts,⁵ they have been implicated as the cause of serious infectious diseases such as meningitis, pneumonia, tracheobronchitis, endocarditis, wound infection and septicaemia, mostly involving the immunocompromised host.⁶ The contribution of *Acinetobacter* to nosocomial infection has been increasing over the past 30 years.⁶⁷ Several outbreaks of hospital infection have been described, some being due to contamination of hospital equipment and the hands of personnel. Treatment of serious *Acinetobacter* spp. infection is further complicated by the widespread multidrug resistance of the organism.7

There has been considerable difficulty in the identification of species within this genus.⁸ Molecular methods may be able to assist with the correct identification over phenotypic methods, particularly for the correct naming of species causing clinically significant disease in this patient population. Hence, it is the aim of this study to identify retrospectively *Acinetobacter* organisms originating from blood culture from patients with haematological malignancy.

A total of 55 isolates belonging to the genus *Acinetobacter* were revived from storage at –80˚C from the culture repository of the Northern Ireland Public Health Laboratory, Belfast City Hospital. These isolates were all originally from blood culture material from haematology/oncology patients at Belfast City Hospital during the period January 2005 to May 2008. All *Acinetobacter* isolates were cultured on Columbia blood agar (Oxoid, Basingstoke, UK) containing 5% (v/v) defibrinated horse blood (CBA+DHB).

All *Acinetobacter* isolates were examined using API20NE (bioMérieux, France). Identification of these isolates was performed in accordance with the manufacturer's instructions. Substrate assimilations were read after 24 and 48 h. Interpretation of the results was carried out after 48 h using the identification software version 6.0. Isolates were classified into one of the following three groups: (i) identification at species level, (ii) identification at genus level, (iii) no identification (i.e., low discrimination). According to the manufacturer's instructions, identification at the species level was divided into four subgroups: (i) excellent species identification (≥99.9% identification,

T≥0.75); (ii) very good species identification (≥99.0% identification, *T*≥0.5); (iii) good species identification (≥90.0% identification, *T*≥0.25; and (iv) acceptable species identification (≥80.0% identification, *T*≥0.0).

All isolates were also identified using the 16S rRNA gene. All DNA isolation procedures were carried out in a Class II biological safety cabinet (MicroFlow) in a room physically separated from that used to set up nucleic acid amplification reaction mixes and also from the 'post-polymerase chain reaction (PCR)' room, in accordance with the Good Molecular Diagnostic Procedures (GMDP) guidelines of Millar *et al.*,⁹ in order to minimise contamination and hence the possibility of false-positive results. Genomic DNA was extracted from a single colony using the Roche High Purity PCR template kit (Roche Diagnostics), in accordance with the manufacturer's instructions. All reaction mixes were set up in a PCR hood in a room separate from that used to extract DNA and from the amplification and post-PCR room to minimise contamination. The PCR reaction mixes (50 µL) contained: 10 mmol/L Tris-HCl (pH 8.3), 50 mmol/L KCl, 2.5 mmol/L MgCl₂, 200μ mol/L (each) dATP, dCTP, dGTP and dTTP, 1.25 units *Thermus aquaticus* (*Taq*) DNA polymerase (Amplitaq, Perkin Elmer), 0.2 µmol/L (each) of the 16S rRNA primers 8FPL and PSR, and 4 µL DNA template containing approximately 50 ng of DNA per mL of extract. Following a 'hot start' (to avoid non-specific priming prior to initial extension), the reaction mixtures were subjected to the following thermal cycling conditions in a Perkin Elmer 2400 thermocycler: 96˚C for 3 min followed by 40 cycles of 96˚C for 1 min, 55˚C for 1 min, 72˚C for 1 min, followed by a final extension at 72˚C for 10 min. During each run, molecular grade water (Biowhittaker) instead of DNA was included randomly as a negative control and *Staphylococcus aureus* DNA was included as a positive control. After amplification, portions (15 µL) were removed, electrophoresed (80 V, 45 min) in agarose gels (Gibco, 2% w/v) in TAE buffer (40 mmol/L Tris, 20 mmol/L acetic acid, 1 mmol/L EDTA [pH 8.3]) and stained with ethidium bromide (5 µg/100 mL). Gels were visualised under ultraviolet (UV) illumination with a gel image analysis system (UVP Products) and all images were archived as digital (*.bmp) graphic files.

Amplicons for sequencing were purified with the QIAquick PCR purification kit (Qiagen) following the manufacturer's instructions and these were then eluted in Tris-HCl (10 mmol/L, pH 8.5) before sequencing. Sequences of the partial regions of all five gene loci were determined using the BigDye Terminator cycle sequencing kit and ABI 3100 genetic analyser. The sequences obtained were compared with those stored in the GenBank data system with BLAST alignment software (www.blast.genome.ad.jp/).

The 16S rRNA gene sequencing was able to assign a species designation to each of the 55 isolates examined, from which seven species were identified (Table 1, Fig. 1). Partial 16S rRNA gene sequences have now been deposited in GenBank for all species identified, with accession numbers FJ263916–FJ263931. API identification was able to assign a species in 44 isolates, where 11 isolates gave two species possibilities (Table 1). In those species that were identified

Fig. 1. Comparison of species identified when using 16S rRNA gene sequencing methods and API20NE phenotyping methods.

phenotypically, three species were noted (Fig. 1). There was a marked difference between the species identified by molecular and phenotypic methods, where only 12 out of the 55 isolate (22%) results concurred between molecular and API methods.

Previous findings indicate that *Acinetobacter* is a relatively uncommon causal agent of bacteraemia in patients with a haematological malignancy or in oncology patients. Jugo *et al.*, ¹⁰ in a previous study at the same hospital in which the current study was performed, showed that the rate of positive blood cultures due to *Acinetobacter* was 3.3% and 2.3% for haematology and oncology patients, respectively.

When using the API20NE scheme, the present results showed that an incorrect result was reported on 78% of isolates examined, when considering the 16S rRNA gene sequencing method as the gold standard. This may be due to **Table 1.** Comparison of 16S rRNA gene sequencing versus API20NE identification of *Acinetobacter* spp.

a lack of phenotypic profiles in the databases which cover all 23 species of *Acinetobacter*, which is in contrast to the relative availability of 16S rRNA gene sequences freely available in GenBank for all 23 named species of *Acinetobacter*. Interestingly, the description of *A. septicus* as a the second most common species of *Acinetobacter* to be identified from blood culture from haematology patients is new, as this species has not been reported previously as a causal agent of bacteraemia in this patient population.

Full and partial 16S rRNA gene sequencing methods have now emerged as valuable tools for identifying phenotypically anomalous isolates. The findings of Bosshard *et al.*¹¹ have shown that 16S rRNA gene sequencing is a more accurate technique for the identification of Gramnegative non-fermenters than is the API20NE system. The results of the current study concur with these findings. Most laboratories will report the isolation of *Acinetobacter* as *A. calcoaceticus–A baumannii* complex (Abc), which is sufficient to direct clinical decision-making. However, specific species are implicated in disease and should not be considered contaminants, especially in the setting of repeatedly positive blood cultures.4

Correct and reliable identification, however, may be important with such organisms, particularly if these environmental organisms are responsible for serious infections associated with immunocompromised patients. As these organisms are likely to be clinically significant in such circumstances, we recommend that molecular identification methods be used where definitive identification is required. When the use of molecular identification methods is justified, employment of partial 16S rDNA PCR and sequencing provides a valuable and reliable method for the identification of *Acinetobacter* spp. \Box

References

1 Bouvet PJ, Grimont PA. Taxonomy of the genus *Acinetobacter* with the recognition of *Acinetobacter baumannii* sp. nov., *Acinetobacter haemolyticus* sp. nov., *Acinetobacter johnsonii* sp. nov., and *Acinetobacter junii* sp. nov. and emended description of *Acinetobacter calcoaceticus* and *Acinetobacter Iwoffii. Int J Syst Bacteriol* 1986; **36**: 228–40.

- 2 Ibrahim A, Gerner-Smidt P, Liesack W. Phylogenetic relationship of the twenty-one DNA groups of the genus *Acinetobacter* as revealed by 16S ribosomal DNA sequence analysis. *Int J Syst Bacteriol* 1997; **47** (3): 837–41.
- 3 Nemec A, De Baere T, Tjernberg I, Vaneechoutte M, van der Reijden TJK, Dijkshoorn L. *Acinetobacter ursingii* sp. nov. and *Acinetobacter schindleri* sp. nov., isolated from human clinical specimens. *Int J Syst Evol Bacteriol* 2001; **51** (Pt 5): 1891–9.
- 4 Allen DM, Hartman BJ, Bennet JE, Mandell GL, Dolin R. *Acinetobacter* species. In: *Mandell, Douglas and Bennett's principles and practice of infectious disease*. 2000, 2339–44.
- 5 Al-Khoja MS, Darrell JH. The skin as the source of *Acinetobacter* and *Moraxella* species occurring in blood cultures. *J Clin Pathol* 1979; **32** (5): 497–9.
- 6 Bergogne-Berezin E, Joly-Guillou ML, Vieu JF. Epidemiology of nosocomial infections due to *Acinetobacter calcoaceticus. J Hosp Infect* 1987; **10** (2): 105–13.
- 7 Bergogne-Berezin E, Joly-Guillou ML. An underestimated nosocomial pathogen, *Acinetobacter calcoaceticus. J Antimicrob Chemother* 1985; **16** (5): 535–8.
- 8 Gundi VA, Dijkshoorn L, Burignat S, Raoult D, La Scola B. Validation of partial *rpoB* gene sequence analysis for the identification of clinically important and emerging *Acinetobacter* species. *Microbiology* 2009; **155** (Pt 7): 2333–41.
- 9 Millar BC, Xu J, Moore JE. Risk assessment models and contamination management: implications for broad-range ribosomal DNA PCR as a diagnostic tool in medical bacteriology. *J Clin Microbiol* 2002; **40** (5): 1575–80.
- 10 Jugo J, Kennedy R, Crowe MJ *et al*. Trends in bacteraemia on the haematology and oncology units of a UK tertiary referral hospital. *J Hosp Infect* 2002; **50** (1): 48–55.
- 11 Bosshard PP, Zbinden R, Abels S, Böddinghaus B, Altwegg M, Böttger EC. 16S rRNA gene sequencing versus the API 20 NE system and the VITEK 2 ID-GNB card for identification of nonfermenting Gram-negative bacteria in the clinical laboratory. *J Clin Microbiol* 2006; **44** (4): 1359–66.